ICU Medical, Inc. develops, manufactures, and sells medical products for infusion therapy, vascular access, and vital care applications. The company's business segments include Consumables, covering infusion therapy, oncology, vascular access, and tracheostomy products, and Infusion Systems, which comprises large volume, ambulatory, and syringe infusion pumps along with dedicated IV sets and safety software. Key product lines include Clave needlefree connectors, ChemoLock and ChemoClave closed system transfer devices, Jelco safety catheters, Port-A-Cath implantable ports, Plum precision infusion pumps, CADD ambulatory pumps, and Medfusion syringe pumps. ICU Medical serves acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities such as home health care providers and long-term care facilities. The company was founded in 1984 and has expanded its portfolio through acquisitions of Pfizer’s Hospira Infusion Systems, Pursuit Vascular, and Smiths Medical. In 2025, ICU Medical formed a joint venture with Otsuka Pharmaceutical Factory America to manage its IV Solutions business, retaining a minority ownership interest while selling and distributing products on behalf of the entity.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage icumed.com
Sector Healthcare IR page ir.icumed.com
Tags
infusion therapy, vascular access, oncology, tracheostomy, closed system transfer devices, needlefree connectors, infusion pumps, ambulatory infusion, syringe infusion, iv solutions, patient monitoring, anesthesia, Clave, MicroClave, NanoClave, Neutron, Tego, ClearGuard, SwabCap, SwabTip, ChemoLock, ChemoClave, Deltec, GRIPPER, Jelco, Safe-T Wing, Port-A-Cath, Portex, PowerWand, Cleo, Portex BLUselect, Portex Bivona, Portex BLUperc, Plum Duo, Plum Solo, Plum 360, PlumSet, LifeShield, CADD, Medfusion, Hospira Infusion Systems, Pursuit Vascular, Smiths Medical, Otsuka ICU Medical LLC
Press page —

Metrics

Valuation  
Market cap $ 4.477B
Market cap (USD) $ 4.477B
P/E 74.58
PEG —
P/BV 2.04
P/S 2.05
P/OCF 16.03
P/FCF 21.46
Dividend yield —
Turnover / mcap —
Returns  
ROE 0.04%
ROI 0.02%
ROIC 0.63%
Profit margin 0.03%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 52.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 2.231B 2.382B 2.259B 2.28B 1.316B 1.271B 1.266B 1.4B 1.293B 379.372M 341.668M 309.26M 313.716M 316.869M 302.195M 284.582M 231.513M 204.726M 188.138M 201.613M 157.532M 75.55M 107.354M 87.807M 69.055M 56.191M
Net profit 732K -117.688M -29.655M -74.286M 103.135M 86.87M 101.035M 28.793M 68.644M 63.084M 44.985M 26.335M 40.418M 41.281M 44.669M 30.929M 26.557M 24.3M 23.079M 25.66M 20.274M 5M 22.297M 19.682M 15.387M 11.788M
Free cash flow 91.804M 124.66M 82.308M -152.44M 198.996M 130.747M 4.606M 67.495M 79.944M 66.58M 41.881M 44.036M 47.311M 47.111M 48.663M 9.924M 31.919M 18.876M 17.867M 11.996M 21.863M 18.182M 12.161M 16.203M 18.095M 8.766M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 142.67 155.17 99.74 157.48 237.34 214.49 187.12 229.63 216 147.35 112.78 81.9 63.71 60.93 45.31 36.49 36.44 33.12 38.6 40.54 40.24 — — — — —
Price performance 12m -0.08 0.56 -0.37 -0.34 0.11 0.15 -0.19 0.06 0.47 0.31 0.38 0.29 0.05 0.34 0.24 0 0.1 -0.14 -0.05 0.01 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 56.2M 113M 176M 202M 124M 106M 222M 162M 183M 181M
↳ YoY growth -2.9% +100.7% +56.4% +14.7% -38.6% -14.7% +109.4% -27.1% +13.2% -1.3%
↳ 5y CAGR +5.2% +18.1% +31.2% +38.9% +16.5% +13.5% +14.5% -1.7% -2.0% +7.8%
Borrowings, current (USD) — — — 0.00 — 0.00 29.7M 51M 51M 18.8M
Borrowings, non-current (USD) 0.00 — — — — 0.00 1.62B 1.58B 1.53B 1.27B
Lease liabilities (USD) — — 0.00 36.3M 2.94M 45.7M 81.8M 75.9M 59.9M 63.6M
Cash and deposits (USD) 445M 290M 345M 269M 396M 553M 209M 254M 309M 308M
Intangible assets (USD) 22.4M 144M 133M 211M 197M 188M 983M 871M 741M 634M
Right-of-use assets (USD) — — 0.00 34.5M 46.6M 39.8M 74.9M 69.9M 53.3M 54.5M
Net debt (borrowings + leases - cash) (USD) -445M — — -261M — -507M 1.53B 1.45B 1.33B 1.04B
Cash flow detail
Operating cash flow (USD) 89.9M 154M 160M 102M 223M 268M -62.1M 166M 204M 180M
Purchases of property, plant and equipment (USD) -23.4M -74.5M -92.7M -97.3M -92M -68.5M -90.3M -83.9M -79.4M -88M
Purchases of intangible assets (USD) -1.19M -5.2M -8.06M -8.73M -8.39M -12.6M -9.02M -9.78M -10.8M -8.97M
Change in receivables (cash effect) (USD) 744,000 -54.5M -76.7M -23.7M 78M 13.8M -19.2M 48.6M -46.8M 8.88M
Change in inventories (cash effect) (USD) -5.5M 182M -21.8M -25M 19.2M 20.8M -201M -6.08M 16.8M -26.3M
Change in payables (cash effect) (USD) -463,000 46.6M 23.3M -2.7M -46.4M 2.35M 37.5M -68.3M 12.5M 7M
Share buybacks (cash effect) (USD) -17.2M -4.06M -6.25M -18.6M -12.9M -8.34M -10.9M -9.35M -12M -8.77M
Interest paid (cash effect) (USD) -118,000 -2.05M -709,000 -549,000 -1.75M -858,000 -63.7M -95.9M -99.7M -83.7M
Income taxes paid (cash effect) (USD) -21.1M -5.11M -12.6M -9.68M -31.6M -19.6M -27.5M -35.8M -25.3M -28.9M
Share-based compensation (USD) 15.2M 19.4M 24.2M 21.9M 24M 27.3M 36M 40.6M 46.9M 55.8M
Operating cash flow before change in receivables (USD) 89.2M 209M 237M 126M 145M 254M -43M 118M 251M 171M
Free cash flow (OCF - PPE - intangibles) (USD) 65.4M 74.7M 59.4M -4.12M 122M 186M -161M 72.5M 114M 82.8M
Income detail
Research and development expense (USD) 13M 51.3M 52.9M 48.6M 42.9M 47.5M 93M 85.3M 88.6M 87.5M
↳ 5y CAGR +8.6% +37.0% +33.6% +21.5% +22.3% +29.7% +12.7% +10.1% +12.8% +15.3%
Total comprehensive income (USD) 62.6M 75M 26.8M 103M 101M 85.4M -136M -1.76M -204M 106M
Comprehensive income to owners (USD) 62.6M 75M 26.8M 103M 101M 85.4M -136M -1.76M -204M 106M
Provision for credit losses (USD) 0.00 2.31M 781,000 14.9M 7.14M 345,000 1.04M 838,000 5.8M —
Credit cost ratio (credit losses / average receivables) (%) 0.0% 2.7% 0.5% 7.9% 4.4% 0.3% 0.6% 0.4% 3.4% —
Reported Mar 16, 2018 Mar 16, 2018 May 10, 2019 May 8, 2020 Feb 26, 2021 May 9, 2022 Feb 27, 2023 Feb 27, 2024 Feb 27, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

ICU Medical Announces Third Quarter 2026 Results Bull 4 Bear 0 Results

and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range

SAN CLEMENTE, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2026.

Third Quarter 2026 Results

Third quarter 2026 GAAP revenue was $560.4 million, as compared to $537.0 million in the same period in the prior year. GAAP gross profit for the third quarter of 2026 was $234.8 million, as compared to $200.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2026 was 42%, as compared to 37% in the same period in the prior year. GAAP net income for the third quarter of 2026 was $26.8 million, or $1.07 per diluted share, as compared to GAAP net loss of $(3.4) million, or $(0.14) per diluted share, for the third quarter of 2025. Adjusted diluted earnings per share for the third quarter of 2026 was $2.44 as compared to $2.03 for the third quarter of 2025. Adjusted EBITDA was $113.9 million for the third quarter of 2026 as compared to $105.9 million for the third quarter of 2025.

October 22, 2026 SAN CLEMENTE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2026 earnings release and conference call. The Company will release its third quarter 2026 results on Thursday, November 5, 2026, at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, November 5, 2026. The call can be accessed at 1-800-245-3047, conference ID “ICUMED”. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will also be available by replay. About ICU Medical ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com.

August 27, 2026 SAN CLEMENTE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on September 9-10, 2026 Company management will attend the Wells Fargo 21st Annual Healthcare Conference, held at the Encore Boston Harbor in Boston, MA, participating in one-on-one meetings on Wednesday, September 9 and Thursday, September 10, 2026. Company management will also participate in a fireside chat on Thursday, September 10, 2026, beginning at 7:15 a.m. PT (10:15 a.m. ET). Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026 Company management will attend the Morgan Stanley 24th Annual Global Healthcare Conference, held at the New York Marriott Marquis in New York, NY, participating in a fireside chat on Tuesday, September 15, 2026, beginning at 4:00 a.m. PT (7:00 a.m. ET), followed by one-on-one meetings. A live audio webcast of the discussions can be accessed by going to the Company’s website at https://ir.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. A replay of the webcasts will be archived on the website for future viewing. About ICU Medical ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com.

Prompts

ICU Medical, Inc. (ticker ICUI), listed in United States.

ETFs Holding ICU Medical, Inc.

ETF Weight in ETF Shares Market value As of
LFSC 2.77% 20,198 $ 3.493M Aug 31, 2026
JPSV 1.25% 2,009 $ 355.412K Nov 17, 2026
SCDS 0.69% 356 $ 62.98K Nov 17, 2026
SMIZ 0.59% 9,293 $ 1.607M Aug 31, 2026
SMDX 0.26% 1,791 $ 325.729K Nov 17, 2026
AVSC 0.25% 43,667 $ 7.942M Nov 16, 2026
DFSV 0.23% 352,419 $ 62.484M Nov 12, 2026
RESM 0.17% 42 $ 6,157.20 Jun 30, 2026
SQLV 0.17% 327 $ 47.938K Jun 30, 2026
PSC 0.15% 24,405 $ 3.578M Jun 30, 2026
DFAT 0.10% 184,508 $ 32.713M Nov 12, 2026
DFAS 0.09% 174,519 $ 30.942M Nov 12, 2026
DXUV 0.03% 8,868 $ 1.572M Nov 12, 2026
MSSM 0.02% 890 $ 153.926K Aug 31, 2026
DFSU 0.02% 2,568 $ 455.306K Nov 12, 2026
DFAC 0.02% 92,044 $ 16.319M Nov 12, 2026
DFUV 0.02% 15,522 $ 2.752M Nov 12, 2026
AVUS 0.01% 4,858 $ 883.524K Nov 16, 2026
DCOR 0.01% 24,204 $ 4.291M Nov 12, 2026
DFAU 0.01% 6,316 $ 1.12M Nov 12, 2026
DFUS 0.01% 7,354 $ 1.304M Nov 12, 2026
EBI 0.00% 94 $ 16.257K Aug 31, 2026
FESM 0.00% 24 $ 3,518.40 Jun 30, 2026
AVSU 0.00% 109 $ 19.824K Nov 16, 2026